Safety results of a phase III trial evaluating ADT plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403)

被引：0
|
作者：
Latorzeff, I.
Esterni, B.
Habibian, M.
Delplanque, G.
Theodore, C.
Baciuchka, M.
Dauba, J.
Laguerre, B.
Krakowski, I.
Gravis, G.
机构：
[1] Clin Pasteur, Toulouse, France
[2] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
[3] Fed Natl Ctr Lutte Canc, Paris, France
[4] Grp Hosp St Joseph, Paris, France
[5] Hop Foch, Suresnes, France
[6] Ctr Hosp Timone, Marseille, France
[7] Hop Layne, Mt De Marsan, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[10] INSERM, Dept Med Oncol, Inst Paoli Calmettes, UMR 891, F-13258 Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4681
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4681
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).
    Haresh, K. P.
    Vjaters, Egils
    Castellano, Daniel
    Olmos, David
    Shore, Neal D.
    Nevalaita, Liina
    Testa, Isabella
    Kappeler, Christian
    Kuss, Iris
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level
    Latorzeff, I.
    Guerif, S.
    Castan, F.
    Meyer, E.
    Supiot, S.
    Lagneau, E.
    Deniaud-Alexandre, E.
    Ronchin, P.
    Benyoucef, A.
    Cartier, L.
    Hamidou, H.
    Crehange, G.
    Pommier, P.
    Magne, N.
    Zibouche, M.
    Gross, E.
    Ploussard, G.
    Salomon, L.
    Sargos, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (05): : 1063 - 1063
  • [23] Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naive Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
    Lavaud, Pernelle
    Gravis, Gwenaelle
    Foulon, Stephanie
    Joly, Florence
    Oudard, Stephane
    Priou, Frank
    Latorzeff, Igor
    Mourey, Loic
    Soulie, Michel
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Theodore, Christine
    Ferrero, Jean Marc
    Beuzeboc, Philippe
    Habibian, Muriel
    Rolland, Frederic
    Deplanque, Gael
    Pouessel, Damien
    Zanetta, Sylvie
    Berdah, Jean Francois
    Dauba, Jerome
    Baciuchka, Marjorie
    Platini, Christian
    Linassier, Claude
    Tubiana-Mathieu, Nicole
    Machiels, Jean Pascal
    El Kouri, Claude
    Ravaud, Alain
    Suc, Etienne
    Eymard, Jean Christophe
    Hasbini, Ali
    Bousquet, Guilhem
    Culine, Stephane
    Boher, Jean-Marie
    Tergemina-Clain, Gabrielle
    Legoupil, Clemence
    Fizazi, Karim
    EUROPEAN UROLOGY, 2018, 73 (05) : 696 - 703
  • [24] Clinical outcome of initially metastatic hormone sensitive prostate cancer (HSPC) in real life population from a single center: Comparison with initially metastatic HSPC patients included in the GETUG-AFU 15 trial
    Guerin, M.
    Sfumato, P.
    Boher, J. M.
    Salem, N.
    Dermeche, S.
    Thomassin, J.
    Fizazi, K.
    Joly, F.
    Oudard, S.
    Habibian, M.
    Culine, S.
    Walz, J.
    Gravis, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S494 - S495
  • [25] China ARCHES: A multicenter phase III randomized doubleblind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) vs PBO plus ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Zhou, F.
    Gongqian, Z.
    Guo, H.
    Hu, Z.
    Zhang, X.
    He, D.
    He, Z.
    Zhang, D.
    Li, Y.
    Kadeerbai, H.
    Liu, Y.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S971 - S971
  • [26] Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
    Machiels, J. H.
    Mazzeo, F.
    Clausse, M.
    Filleul, B.
    Marcelis, L.
    Honhon, B.
    D'Hondt, L.
    Dopchie, C.
    Bonny, M.
    Kerger, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial
    Yang, Xiangwei
    Chen, Hong
    Xu, Duanya
    Chen, Xianju
    Li, Yamei
    Tian, Jun
    Wang, Dongwen
    Pang, Jun
    BMC CANCER, 2022, 22 (01)
  • [28] Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial
    Xiangwei Yang
    Hong Chen
    Duanya Xu
    Xianju Chen
    Yamei Li
    Jun Tian
    Dongwen Wang
    Jun Pang
    BMC Cancer, 22
  • [29] A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects
    Xie, Wanling
    Chahoud, Jad
    Emamekhoo, Hamid
    Mckay, Rana R.
    Marshall, Catherine Handy
    Einstein, David Johnson
    Lang, Joshua Michael
    Raymond, Sarah
    Roberts, Daniel Aaron
    Sunkara, Rajitha
    Ravi, Praful
    Tewari, Alok
    Pomerantz, Mark
    Dong, Fei
    Siegmund, Stephanie
    Rodig, Scott J.
    Pfaff, Kathleen L.
    Sweeney, Christopher
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS244 - TPS244
  • [30] Identification of prognostic groups in patients with hormone-sensitive metastatic prostate cancer at the present time: An analysis of the GETUG 15 phase III trial
    Gravis, Gwenaelle
    Fizazi, Karim
    Joly, Florence
    Oudard, Stephane
    Priou, Frank
    Latorzeff, Igor
    Delva, Remy
    Krakowski, Ivan
    Laguerre, Brigitte
    Rolland, Frederic
    Theodore, Christine
    Deplanque, Gael
    Ferrero, Jean-Marc
    Pouessel, Damien
    Mourey, Loic
    Beuzeboc, Philippe
    Zanetta, Sylvie
    Esterni, Benjamin
    Habibian, Muriel
    Soulie, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345